Topical glaucoma therapy cost in Mexico
- PMID: 23846765
- DOI: 10.1007/s10792-013-9823-6
Topical glaucoma therapy cost in Mexico
Abstract
Glaucoma is an important cause of irreversible blindness that represents a significant economic burden; most direct costs of glaucoma are drug-related. We calculated the annual cost of some of the most commonly prescribed glaucoma medications in Mexico, according to their average wholesale price (AWP) and dose regimen. Annual costs ranged from USD4.97 for Imot 15 ml (timolol 0.5 %; Laboratorios Sophia) to USD675.39 for Alphagan 5 ml (brimonidine 0.2 %; Allergan, Inc.). β-Blockers were the least expensive glaucoma medications (range USD20.44-55.44). Alphagan 5 ml was 250 % more expensive than other selective α(2)-agonists. Of the carbonic anhydrase inhibitors, dorzolamide 2 % was less expensive than brinzolamide 1 % (USD326.91 vs. USD418.96). The annual cost for prostaglandin analogs ranged from USD235.58 for bimatoprost 0.03 % to USD337.78 for latanoprost 0.005 %. Some fixed combinations were less expensive than separate combinations. The average annual cost for all treatments increased by 27.87 ± 10.09 % between 2009 and 2012. Annual glaucoma therapy cost seems to be lower in Mexico than in other countries, due to a lower AWP, especially for some medications made by Mexican laboratories.
Similar articles
-
Medical therapy cost considerations for glaucoma.Am J Ophthalmol. 2003 Jul;136(1):18-25. doi: 10.1016/s0002-9394(03)00102-8. Am J Ophthalmol. 2003. PMID: 12834665 Clinical Trial.
-
Daily cost of glaucoma medications in China.J Glaucoma. 2007 Oct-Nov;16(7):594-7. doi: 10.1097/IJG.0b013e318064c818. J Glaucoma. 2007. PMID: 18091176
-
Cost considerations of medical therapy for glaucoma.Am J Ophthalmol. 1999 Oct;128(4):426-33. doi: 10.1016/s0002-9394(99)00235-4. Am J Ophthalmol. 1999. PMID: 10577583
-
Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario.Can J Ophthalmol. 2018 Apr;53(2):173-187. doi: 10.1016/j.jcjo.2017.08.003. Epub 2017 Sep 27. Can J Ophthalmol. 2018. PMID: 29631831 Review.
-
Primary drug treatment for glaucoma: beta-blockers versus other medications.Surv Ophthalmol. 2002 Jan-Feb;47(1):63-73. doi: 10.1016/s0039-6257(01)00286-7. Surv Ophthalmol. 2002. PMID: 11801272 Review.
Cited by
-
Glaucoma Medication Preferences among Glaucoma Specialists in Mexico.J Curr Glaucoma Pract. 2017 Sep-Dec;11(3):97-100. doi: 10.5005/jp-journals-10028-1232. Epub 2017 Oct 27. J Curr Glaucoma Pract. 2017. PMID: 29151684 Free PMC article.
-
A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma.Ophthalmol Ther. 2018 Jun;7(1):145-156. doi: 10.1007/s40123-018-0128-8. Epub 2018 Apr 21. Ophthalmol Ther. 2018. PMID: 29680880 Free PMC article.
-
A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery.JAMA Ophthalmol. 2018 Nov 1;136(11):1271-1279. doi: 10.1001/jamaophthalmol.2018.3672. JAMA Ophthalmol. 2018. PMID: 30178000 Free PMC article.
-
From Eye Care to Hair Growth: Bimatoprost.Pharmaceuticals (Basel). 2024 Apr 27;17(5):561. doi: 10.3390/ph17050561. Pharmaceuticals (Basel). 2024. PMID: 38794131 Free PMC article. Review.
-
Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes.J Health Econ Outcomes Res. 2024 Jan 23;11(1):8-22. doi: 10.36469/001c.91396. eCollection 2024. J Health Econ Outcomes Res. 2024. PMID: 38500521 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical